Antiepileptic drugs trials: neonates and infants

Area of Science:

• Pediatric Neurology
• Clinical Pharmacology
• Epileptology

Background:

• Anti-epileptic drug (AED) testing presents unique challenges in pediatric populations.
• Pharmacokinetics, pharmacodynamics, neurochemistry, and developmental factors necessitate specialized testing in infants with refractory seizures.
• Electroencephalogram (EEG) monitoring and clinical semiology are crucial for defining seizure types and frequency changes.

Purpose of the Study:

• To outline appropriate trial designs for AED testing in various infant populations.
• To address specific considerations for neonatal seizures, partial seizures in young infants, and uncommon epileptic encephalopathies.
• To propose outcome measures for evaluating AED efficacy and tolerability in pediatric epilepsy.

Main Methods:

• For neonatal seizures, trial designs should mirror status epilepticus protocols, with endpoints like seizure cessation or time to next seizure.
• For partial seizures in young infants, placebo-controlled, double-blind studies with fixed doses and 48-hour video EEG quantification are suggested.
• For encephalopathic epilepsies, randomized sequential monotherapy with dose titration based on seizure control or tolerance is proposed.

Main Results:

• Trial designs should prioritize seizure cessation, time to next seizure, seizure reduction, tolerability, and duration of AED treatment.
• The use of placebo in neonatal seizure trials is considered questionable.
• Video EEG is essential for quantifying seizure activity in pediatric epilepsy trials.

Conclusions:

• Tailored clinical trial methodologies are essential for evaluating AEDs in diverse pediatric epilepsy populations.
• Outcome variables should encompass seizure control, tolerability, and treatment duration.
• Standardized approaches, including EEG monitoring, are vital for robust evidence generation in pediatric AED research.